Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 282-287

  Min, David I ^a   Perry, Paul J ^a   Chen, Hsiang Yin ^a   Hunsicker, Lawrence G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; THYMOCYTE ANTIBODY;

ACCURACY; ADULT; AGED; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PATIENT MONITORING;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031919768     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983;309:809-15.
2. Canafax DM, Min DI, Gruber SA, et al. Immunosuppression for cadaveric renal allograft recipients: a risk-factor matched comparison of the Minnesota randomized trial with an antilymphoblast globulin, azathioprine, cyclosporine and prednisone protocol. Clin Transplant 1989;3:110-19.
3. Fahr A. Cyclosporine clinical pharmacokinetics. Clin Pharmacokinet 1993;24(6):472-95.
4. Kahan BD. Cyclosporine. N Engl J Med 1989;321:1725-8.
5. Robinson CA, Ketchum CH. Monitoring of cyclosporine A: is it possible? [letter]. Ther Drug Monit 1983;5:371-2.
6. Lindholm A, Dahlqvist R, Groth GG, Sjörqvist F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990;30:443-52.
7. Moyer TP, Post GR, Sterioff S, Anderson CF. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc 1988;63:241-7.
8. Taube DH, Neild GH, Williams DG, et al. Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal transplant recipients. Lancet 1985;2:171-4.
9. Rogerson ME, Marsden JT, Reid KE, Bewick M, Holt DW. Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation 1986;41;276-8.
10. Nankivell B, Hibbins M, Chapman JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994;58: 989-96.
11. Lindholm A. Therapeutic monitoring of cyclosporin - an update. Eur J Clin Pharmacol 1991;41:273-83.
12. Bowers LD. Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. Clin Biochem 1991;24:81-7.
13. Kahan BD, Shaw LM, Holt D, Grevel J, Johnston A. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Clin Chem 1990;36:1510-16.
14. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver operating characteristic (ROC) curves. Med Decis Making 1984;4:137-50.
15. Mossman D, Somoza E. ROC curves, test accuracy and the description of diagnostic tests. J Neuropsychiatry 1991;3: 330-3.
16. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994;14:230-40.
17. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-98.
18. Jelliffe RW. Estimation of creatine clearance when urine cannot be collected. Lancet 1971;1:975-6.
19. Sawchuck RJ, Cartier LL. Liquid-chromatographic determination of cyclosporine A in blood and plasma. Clin Chem 1981;27:1368-71.